PB0776 Characterization of the Effects of Hydroxyurea and Crizanlizumab on Plasma Immunothrombosis Biomarkers in Patients with Sickle Cell Disease
Veronica Bochenek(Children's Hospital of Philadelphia), Kandace Gollomp(Children's Hospital of Philadelphia), Magdalena Kowalska, Norman Levine(College of Charleston), Osheiza Abdulmalik(Children's Hospital of Philadelphia), Jie Wu(Army Medical University), J. Weaver, An Ngo, A M Roe, Marjorie Risman
Cited by 0
Related Papers
In vivo hematopoietic stem cell modification by mRNA delivery
|Science|2023|321
5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells<sup>†,‡</sup>
|British Journal of Haematology|2005|244
Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells
|Science|2018|159
Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression
|Journal of Clinical Investigation|2014|125
Investigating the magnetic susceptibility properties of fresh human blood for noninvasive oxygen saturation quantification
|Magnetic Resonance in Medicine|2011|115